CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Fitch: Biologics Driving Revenue Gains for U.S. Pharmaceutical Companies

[July 29, 2014]

Fitch: Biologics Driving Revenue Gains for U.S. Pharmaceutical Companies

CHICAGO --(Business Wire)--

Fitch Ratings expects that revenues from biologic therapies as a percentage of total pharmaceutical sales will continue to increase over the intermediate term as companies increase their prominence in their drug portfolios, according to a report published today.

Biologics drug sales for the six major U.S. pharmaceutical companies increased to approximately 36% from 27% over the last three years, as the number of FDA approvals has outpaced traditional small molecule approvals.

Fitch believes that biologics will fare better than small molecule drugs after patent expirations. The price discounts and market share gains of biosimilars will be less than those in the traditional generic market, because most approved biosimilars probably will not be automatically interchangeable with the original reference biologic early on. Nevertheless, Fitch believes biosimilar manufacturers, pharmacy benefit managers and drug distributors will have financial incentives to take share from the originator therapy.

Furthermore, the number of biologics in branded pharmaceutical companies' pipelines has and should continue to account for a greater portion of the number of total pipeline projects.

From a credit perspective, biologics are supportive for the credit profiles of the branded pharmaceutical industry by offering opportunities for growth, support for profitability and greater operational stability in the inermediate term.

The full report 'Biologics on the Rise' is available at 'www.fitchratings.com.'

Additional information is available at 'www.fitchratings.com'.

Applicable Criteria and Related Research: Biologics on the Rise (A Tailwind for Branded Pharmaceuticals)

http://www.fitchratings.com/creditdesk/reports/report_frame.cfm?rpt_id=753172

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON (News - Alert) THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter